MacroGenics, Inc. MGNX
2.33 USD +0.11 (+4.95%)
At closeNov 6, 2026, 4:01 PM EST
2.33 0.00 0.00%
After hours · Nov 6, 4:01 PM ET
2.25 Day range 2.45
1.33 52-week range 4.86
- YTD
- +44.72%
- 1 year
- +71.32%
News
globenewswire.com MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D. ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily…
benzinga.com MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first…
benzinga.com B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11 B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.
benzinga.com UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of…- benzinga.com MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead…
benzinga.com MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27 MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the…- benzinga.com MacroGenics To Receive $24.5M Milestone From Sanofi Following FDA Approval Of TZIELD Expansion In Type 1 Diabetes MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will…
benzinga.com Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 9.38 percent. This is a 10.77 percent increase over losses of $(0.65)…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.- benzinga.com MacroGenics Enters Into Expanded Royalty Purchase Agreement With Sagard In Exchange For Capped Royalty Interest On Future Global Net Sales Of ZYNYZ MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered…
- benzinga.com Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6 Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4 • Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers• On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc.…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4 Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $3 to $4.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Is MacroGenics Stock Sinking Tuesday? MacroGenics sees stock decline after FDA places partial clinical hold on Phase 2 LINNET study due to safety concerns.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Macrogenics Q3 EPS $0.27 Beats $(0.58) Estimate, Sales $72.839M Beat $14.700M Estimate Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.58) by 146.31 percent. This is a 70 percent decrease over earnings of $0.90…- benzinga.com HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $2 price target.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com MacroGenics Forged A ZYNYZ Royalty Purchase Deal With Sagard Healthcare Partners For $70M Upfront Payment, Extending Cash Runway Through First Half Of 2027 MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the…
- benzinga.com 4 Analysts Assess Macrogenics: What You Need To Know
- benzinga.com B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3 B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target from $5 to $3.
- benzinga.com Stifel Maintains Hold on Macrogenics, Lowers Price Target to $5 Stifel analyst Stephen Willey maintains Macrogenics (NASDAQ:MGNX) with a Hold and lowers the price target from $6 to $5.
- benzinga.com Barclays Maintains Overweight on Macrogenics, Lowers Price Target to $3 Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $8 to $3.
benzinga.com Macrogenics Q1 EPS $(0.65) Beats $(0.76) Estimate, Sales $13.19M Beat $6.17M Estimate Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.76) by 14.47 percent. This is a 22.62 percent increase over losses of $(0.84)…
benzinga.com Earnings Scheduled For May 13, 2025 - benzinga.com A Look at Macrogenics's Upcoming Earnings Report
- benzinga.com HC Wainwright & Co. Maintains Neutral on Macrogenics, Lowers Price Target to $2 HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target from $4 to $2.
- benzinga.com Earnings Scheduled For March 20, 2025
- benzinga.com Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights
- benzinga.com JMP Securities Downgrades Macrogenics to Market Perform JMP Securities analyst Silvan Tuerkcan downgrades Macrogenics (NASDAQ:MGNX) from Market Outperform to Market Perform.
benzinga.com HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Macrogenics Q3 EPS $0.90 Beats $0.21 Estimate, Sales $110.71M Beat $76.11M Estimate Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.21 by 328.57 percent. This is a 221.43 percent increase over earnings of $0.28…
- benzinga.com Macrogenics Earnings Preview
- benzinga.com Macrogenics Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
- benzinga.com HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.
- benzinga.com Reported Sunday, MacroGenics Presents Efficacy And Safety Data For Vobra Duo In Phase 2 TAMARACK Study At ESMO 2024 Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra duo through a median of 6 doses (ranging up to 12),…
- benzinga.com Reported Sunday, MacroGenics To Present Phase 2 Results From TAMARACK Trial On Innovative Cancer Treatment At ESMO 2024 MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer,…
- benzinga.com HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.
- benzinga.com Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Akamai Technologies Issues Weak Outlook, Joins Applied Optoelectronics, JFrog And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- benzinga.com Earnings Scheduled For March 7, 2024 Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.